{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:44:59Z","timestamp":1774791899182,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2005,3,4]],"date-time":"2005-03-04T00:00:00Z","timestamp":1109894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,3,4]],"date-time":"2005-03-04T00:00:00Z","timestamp":1109894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1038\/sj.cgt.7700823","type":"journal-article","created":{"date-parts":[[2005,3,4]],"date-time":"2005-03-04T10:08:12Z","timestamp":1109930892000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Rae","family":"Myers","sequence":"first","affiliation":[]},{"given":"Suzanne","family":"Greiner","sequence":"additional","affiliation":[]},{"given":"Mary","family":"Harvey","sequence":"additional","affiliation":[]},{"given":"Diane","family":"Soeffker","sequence":"additional","affiliation":[]},{"given":"Marie","family":"Frenzke","sequence":"additional","affiliation":[]},{"given":"Katalin","family":"Abraham","sequence":"additional","affiliation":[]},{"given":"Alan","family":"Shaw","sequence":"additional","affiliation":[]},{"given":"Shmuel","family":"Rozenblatt","sequence":"additional","affiliation":[]},{"given":"Mark J","family":"Federspiel","sequence":"additional","affiliation":[]},{"given":"Stephen J","family":"Russell","sequence":"additional","affiliation":[]},{"given":"Kah-Whye","family":"Peng","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,3,4]]},"reference":[{"key":"BF7700823_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BF7700823_CR2","doi-asserted-by":"crossref","unstructured":"NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273:493\u2013497.","DOI":"10.1001\/jama.273.6.491"},{"key":"BF7700823_CR3","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0090-8258(03)00472-4","volume":"90","author":"GC Stuart","year":"2003","unstructured":"Stuart GC . First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol. 2003;90:S8\u2013S15.","journal-title":"Gynecol Oncol"},{"key":"BF7700823_CR4","first-page":"437","volume":"5","author":"SJ Russell","year":"1994","unstructured":"Russell SJ . Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol. 1994;5:437\u2013443.","journal-title":"Semin Cancer Biol"},{"key":"BF7700823_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/89901","volume":"7","author":"D Kirn","year":"2001","unstructured":"Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7:781\u2013787.","journal-title":"Nat Med"},{"key":"BF7700823_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1566523024605582","volume":"2","author":"JC Bell","year":"2002","unstructured":"Bell JC, Garson KA, Lichty BD, et al. Oncolytic viruses: programmable tumour hunters. Curr Gene Ther. 2002;2:243\u2013254.","journal-title":"Curr Gene Ther"},{"key":"BF7700823_CR7","doi-asserted-by":"crossref","unstructured":"Everts B, Poel HG . Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2004 [Epub ahead of print].","DOI":"10.1038\/sj.cgt.7700771"},{"key":"BF7700823_CR8","first-page":"4656","volume":"62","author":"KW Peng","year":"2002","unstructured":"Peng KW, TenEyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656\u20134662.","journal-title":"Cancer Res"},{"key":"BF7700823_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nm0502-527","volume":"8","author":"KW Peng","year":"2002","unstructured":"Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ . Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002;8:527\u2013531.","journal-title":"Nat Med"},{"key":"BF7700823_CR10","first-page":"1401","volume-title":"Fields Virology","author":"D Griffin","year":"2001","unstructured":"Griffin D . Measles Virus. In: Fielding B, Knipe D, Howley P, eds. Fields Virology. 4th ed. Philadelphia: Lippincott-Raven Publishers; 2001: 1401\u20131441."},{"key":"BF7700823_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1089\/104303401750148766","volume":"12","author":"E Galanis","year":"2001","unstructured":"Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001;12:811\u2013821.","journal-title":"Hum Gene Ther"},{"key":"BF7700823_CR12","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1128\/jvi.69.6.3955-3958.1995","volume":"69","author":"LM Esolen","year":"1995","unstructured":"Esolen LM, Park SW, Hardwick JM, Griffin DE . Apoptosis as a cause of death in measles virus-infected cells. J Virol. 1995;69:3955\u20133958.","journal-title":"J Virol"},{"key":"BF7700823_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nbt942","volume":"22","author":"T Nakamura","year":"2004","unstructured":"Nakamura T, Peng KW, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol. 2004;22:331\u2013336.","journal-title":"Nat Biotechnol"},{"key":"BF7700823_CR14","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","volume":"14","author":"F Radecke","year":"1995","unstructured":"Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J. 1995;14:5773\u20135784.","journal-title":"EMBO J"},{"key":"BF7700823_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0168-1702(94)90025-6","volume":"31","author":"JS Rota","year":"1994","unstructured":"Rota JS, Wang ZD, Rota PA, et al. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res. 1994;31:317\u2013330.","journal-title":"Virus Res"},{"key":"BF7700823_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1128\/JVI.75.2.910-920.2001","volume":"75","author":"CL Parks","year":"2001","unstructured":"Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA . Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol. 2001;75:910\u2013920.","journal-title":"J Virol"},{"key":"BF7700823_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/35022579","volume":"406","author":"H Tatsuo","year":"2000","unstructured":"Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406:893\u2013897.","journal-title":"Nature"},{"key":"BF7700823_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","volume":"75","author":"RE Dorig","year":"1993","unstructured":"Dorig RE, Marcil A, Chopra A, Richardson CD . The human CD46\u2009molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75:295\u2013305.","journal-title":"Cell"},{"key":"BF7700823_CR19","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1128\/jvi.67.10.6025-6032.1993","volume":"67","author":"D Naniche","year":"1993","unstructured":"Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67:6025\u20136032.","journal-title":"J Virol"},{"key":"BF7700823_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9","volume":"70","author":"L Bjorge","year":"1997","unstructured":"Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S . Complement-regulatory proteins in ovarian malignancies. Int J Cancer. 1997;70:14\u201325.","journal-title":"Int J Cancer"},{"key":"BF7700823_CR21","first-page":"1305","volume-title":"Fields Virology","author":"RA Lamb","year":"2001","unstructured":"Lamb RA, Kolakofsky D . Paramyxoviridae: the viruses and their replication. In: Fielding B, Knipe D, Howley P, eds. Fields Virology. 4th edn. Philadelphia: Lippincott-Raven Publishers; 2001: 1305\u20131340."},{"key":"BF7700823_CR22","first-page":"1381","volume-title":"Fields Virology","author":"KM Carbone","year":"2001","unstructured":"Carbone KM, Wolinsky JS . Mumps Virus. In: Fielding B, Knipe D, Howley P, eds. Fields Virology. 4th edn. Philadelphia: Lippincott-Raven Publishers; 2001: 1381\u20131400."},{"key":"BF7700823_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1006\/excr.1997.3861","volume":"238","author":"CA Conover","year":"1998","unstructured":"Conover CA, Hartmann LC, Bradley S, et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998;238:439\u2013449.","journal-title":"Exp Cell Res"},{"key":"BF7700823_CR24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1128\/JVI.72.2.1224-1234.1998","volume":"72","author":"T Cathomen","year":"1998","unstructured":"Cathomen T, Naim HY, Cattaneo R . Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol. 1998;72:1224\u20131234.","journal-title":"J Virol"},{"key":"BF7700823_CR25","first-page":"2462","volume":"63","author":"LK Phuong","year":"2003","unstructured":"Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003;63:2462\u20132469.","journal-title":"Cancer Res"},{"key":"BF7700823_CR26","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","volume":"64","author":"BD Anderson","year":"2004","unstructured":"Anderson BD, Nakamura T, Russell SJ, et al. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64:4919\u20134926.","journal-title":"Cancer Res"},{"key":"BF7700823_CR27","doi-asserted-by":"publisher","first-page":"15590","DOI":"10.1073\/pnas.242134499","volume":"99","author":"YL Lin","year":"2002","unstructured":"Lin YL, Mettling C, Portales P, et al. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA. 2002;99:15590\u201315595.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF7700823_CR28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/jvi.71.2.873-882.1997","volume":"71","author":"SL Kozak","year":"1997","unstructured":"Kozak SL, Platt EJ, Madani N, et al. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol. 1997;71:873\u2013882.","journal-title":"J Virol"},{"key":"BF7700823_CR29","first-page":"325","volume":"59","author":"Y Li","year":"1999","unstructured":"Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325\u2013330.","journal-title":"Cancer Res"},{"key":"BF7700823_CR30","first-page":"2953","volume":"61","author":"TP Cripe","year":"2001","unstructured":"Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001;61:2953\u20132960.","journal-title":"Cancer Res"},{"key":"BF7700823_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1006\/mthe.2002.0599","volume":"5","author":"A Kanerva","year":"2002","unstructured":"Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther. 2002;5:695\u2013704.","journal-title":"Mol Ther"},{"key":"BF7700823_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.gt.3301115","volume":"7","author":"TJ Wickham","year":"2000","unstructured":"Wickham TJ . Targeting adenovirus. Gene Ther. 2000;7:110\u2013114.","journal-title":"Gene Ther"},{"key":"BF7700823_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1365-2362.1999.00485.x","volume":"29","author":"P Sillanaukee","year":"1999","unstructured":"Sillanaukee P, Ponnio M, Jaaskelainen IP . Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Invest. 1999;29:413\u2013425.","journal-title":"Eur J Clin Invest"},{"key":"BF7700823_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1046\/j.1365-2249.2003.02066.x","volume":"131","author":"N Donin","year":"2003","unstructured":"Donin N, Jurianz K, Ziporen L, et al. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131:254\u2013263.","journal-title":"Clin Exp Immunol"},{"key":"BF7700823_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.iy.09.040191.002243","volume":"9","author":"MK Liszewski","year":"1991","unstructured":"Liszewski MK, Post TW, Atkinson JP . Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol. 1991;9:431\u2013455.","journal-title":"Annu Rev Immunol"},{"key":"BF7700823_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0167-5699(99)01537-6","volume":"20","author":"A Gorter","year":"1999","unstructured":"Gorter A, Meri S . Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999;20:576\u2013582.","journal-title":"Immunol Today"},{"issue":"2\u20134","key":"BF7700823_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","volume":"40","author":"Z Fishelson","year":"2003","unstructured":"Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003;40 (2\u20134):109\u2013123.","journal-title":"Mol Immunol"},{"key":"BF7700823_CR38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/sj.cgt.7700535","volume":"9","author":"SJ Russell","year":"2002","unstructured":"Russell SJ . RNA viruses as virotherapy agents. Cancer Gene Ther. 2002;9:961\u2013966.","journal-title":"Cancer Gene Ther"},{"key":"BF7700823_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1568009013334223","volume":"1","author":"TK Yoon","year":"2001","unstructured":"Yoon TK, Shichinohe T, Laquerre S, et al. Selectively replicating adenoviruses for oncolytic therapy. Curr Cancer Drug Targets. 2001;1:85\u2013107.","journal-title":"Curr Cancer Drug Targets"},{"issue":"Suppl 1","key":"BF7700823_CR40","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1002\/jgm.502","volume":"6","author":"JJ Cornelis","year":"2004","unstructured":"Cornelis JJ, Salome N, Dinsart C, Rommelaere J . Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med. 2004;6 (Suppl 1):S193\u2013S202.","journal-title":"J Gene Med"},{"key":"BF7700823_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1535-6108(03)00251-4","volume":"4","author":"MA Giedlin","year":"2003","unstructured":"Giedlin MA, Cook DN, Dubensky Jr TW . Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? Cancer Cell. 2003;4:241\u2013243.","journal-title":"Cancer Cell"},{"key":"BF7700823_CR42","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.2741\/976","volume":"8","author":"G Fulci","year":"2003","unstructured":"Fulci G, Chiocca EA . Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci. 2003;8:e346\u2013e360.","journal-title":"Front Biosci"},{"issue":"Suppl","key":"BF7700823_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1679\/aohc.53.Suppl_165","volume":"53","author":"ML Cranshaw","year":"1990","unstructured":"Cranshaw ML, Leak LV . Milky spots of the omentum: a source of peritoneal cells in the normal and stimulated animal. Arch Histol Cytol. 1990;53 (Suppl):165\u2013177.","journal-title":"Arch Histol Cytol"},{"key":"BF7700823_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0923-2494(05)80072-0","volume":"143","author":"JF Wijffels","year":"1992","unstructured":"Wijffels JF, Hendrickx RJ, Steenbergen JJ, et al. Milky spots in the mouse omentum may play an important role in the origin of peritoneal macrophages. Res Immunol. 1992;143:401\u2013409.","journal-title":"Res Immunol"},{"key":"BF7700823_CR45","first-page":"687","volume":"53","author":"A Hagiwara","year":"1993","unstructured":"Hagiwara A, Takahashi T, Sawai K, et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993;53:687\u2013692.","journal-title":"Cancer Res"},{"key":"BF7700823_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/ejso.2001.1117","volume":"27","author":"CAM Lopes","year":"2001","unstructured":"Lopes CAM, Gupta A, Koppe MJ, et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol. 2001;27:359\u2013363.","journal-title":"Eur J Surg Oncol"},{"key":"BF7700823_CR47","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","volume":"34","author":"T Asada","year":"1974","unstructured":"Asada T . Treatment of human cancer with mumps virus. Cancer. 1974;34:1907\u20131928.","journal-title":"Cancer"},{"key":"BF7700823_CR48","first-page":"37","volume":"21","author":"Y Okuno","year":"1978","unstructured":"Okuno Y, Asada T, Yamanishi K, et al. Studies on the use of mumps virus for treatment of human cancer. Biken J. 1978;21:37\u201349.","journal-title":"Biken J"},{"key":"BF7700823_CR49","first-page":"487","volume":"12","author":"Y Shimizu","year":"1988","unstructured":"Shimizu Y, Hasumi K, Okudaira Y, et al. Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev. 1988;12:487\u2013495.","journal-title":"Cancer Detect Prev"},{"key":"BF7700823_CR50","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1128\/JVI.74.11.5382-5384.2000","volume":"74","author":"SA Rubin","year":"2000","unstructured":"Rubin SA, Pletnikov M, Taffs R, et al. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol. 2000;74:5382\u20135384.","journal-title":"J Virol"},{"key":"BF7700823_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biologicals.2004.08.003","volume":"32","author":"S Saika","year":"2004","unstructured":"Saika S, Kidokoro M, Aoki A, et al. Neurovirulence of mumps virus: intraspinal inoculation test in marmosets. Biologicals. 2004;32:147\u2013152.","journal-title":"Biologicals"},{"key":"BF7700823_CR52","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","volume":"103","author":"D Dingli","year":"2004","unstructured":"Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103:1641\u20131646.","journal-title":"Blood"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/7700823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700823","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:25:54Z","timestamp":1647955554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/7700823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,4]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7,1]]}},"alternative-id":["BF7700823"],"URL":"https:\/\/doi.org\/10.1038\/sj.cgt.7700823","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,4]]},"assertion":[{"value":"22 August 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2005","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}